- Home
- IMVT vs SRRK Comparison
IMVT vs SRRK Comparison
Compare IMVT & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMVT
- SRRK
- Stock Information
- Founded
- IMVT N/A
- SRRK 2012
- Country
- IMVT United States
- SRRK United States
- Employees
- IMVT N/A
- SRRK N/A
- Industry
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- SRRK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IMVT Health Care
- SRRK Health Care
- Exchange
- IMVT Nasdaq
- SRRK Nasdaq
- Market Cap
- IMVT 4.2B
- SRRK 4.2B
- IPO Year
- IMVT N/A
- SRRK 2018
- Fundamental
- Price
- IMVT $26.77
- SRRK $42.97
- Analyst Decision
- IMVT Strong Buy
- SRRK Strong Buy
- Analyst Count
- IMVT 11
- SRRK 7
- Target Price
- IMVT $48.10
- SRRK $40.43
- AVG Volume (30 Days)
- IMVT 799.9K
- SRRK 1.2M
- Earning Date
- IMVT 02-10-2025
- SRRK 11-12-2024
- Dividend Yield
- IMVT N/A
- SRRK N/A
- EPS Growth
- IMVT N/A
- SRRK N/A
- EPS
- IMVT N/A
- SRRK N/A
- Revenue
- IMVT N/A
- SRRK N/A
- Revenue This Year
- IMVT N/A
- SRRK N/A
- Revenue Next Year
- IMVT N/A
- SRRK N/A
- P/E Ratio
- IMVT N/A
- SRRK N/A
- Revenue Growth
- IMVT N/A
- SRRK N/A
- 52 Week Low
- IMVT $24.61
- SRRK $6.76
- 52 Week High
- IMVT $45.58
- SRRK $46.19
- Technical
- Relative Strength Index (RSI)
- IMVT 44.77
- SRRK 69.26
- Support Level
- IMVT $26.19
- SRRK $40.95
- Resistance Level
- IMVT $28.08
- SRRK $44.22
- Average True Range (ATR)
- IMVT 1.01
- SRRK 2.57
- MACD
- IMVT -0.03
- SRRK -0.12
- Stochastic Oscillator
- IMVT 32.73
- SRRK 73.14
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.